

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **nDatalyze Corp.** (the “Issuer”).

Trading Symbol: **NDAT**

Number of Outstanding Listed Securities: **41,027,425**

Date: **January 01, 2024**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continues the clinical study process for its YMI mental health system. In furtherance thereof, formal agreements have been signed related to DNA data acquisition, and Dr. Dale Stevens, with regard to analysis of DNA data correlation with biometric data. Questionnaire answer collection related to existing DNA records are expected to complete in January, 2024. The Issuer also signed a Letter of Intent with the Canadian Mental Health Association and Dr's A. Greenshaw and Bo Cao related to the assessment and calibration of the Issuers mental condition diagnostic approach. The Issuer continues the liquidation of its extractor inventory.

2. Provide a general overview and discussion of the activities of management.

Management continues to focus on the YMI mental health platform and tasks related to the related clinical study.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

No new products are offered or in development.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Formal agreements have been signed related to DNA data acquisition, and Dr. Dale Stevens, with regard to analysis of DNA data correlation with biometric data. Questionnaire answer collection related to existing DNA records are expected to complete in January, 2024. The Issuer also signed a Letter of Intent with the Canadian Mental Health Association and Dr's A. Greenshaw and Bo Cao related to the assessment and calibration of the Issuers mental condition diagnostic approach. These are unrelated parties to the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer did not acquire or dispose of any material assets during the period.

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer has no employees - all activities are contract-based.

11. Report on any labour disputes and resolutions of those disputes if applicable.

No such developments have occurred during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer was not a party to any legal proceedings during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Beyond usual accounts payable, the Issuer has no debt. This said, the Issuer is in a dispute over approximately \$200,000 in fees charged by its former marketing contractor. The Issuer does not believe that this amount is being pursued by the marketing company and the Issuer has re-allocated the whole amount on its financial statements.

14. Provide details of any securities issued and options or warrants granted.

None

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends that are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The mental health crisis continues and this is expected to contribute to the YMI platform's acceptance going forward. There is no guarantee the YMI mental health platform will prove commercially viable.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer that has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **January 1, 2024**

James M. Durward
Name of Director or Senior Officer

“James M. Durward”
Signature

Chief Executive Officer
Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report - YY/MM/DD
Name of Issuer nDatalyze Corp.	December 2023	2024/01/01
Issuer Address 1150, 707 – 7 th Avenue SW		
City/Province/Postal Code Calgary, Alberta T2P 3H6	Issuer Fax No. N/A	Issuer Telephone No. 403-689-3901
Contact Name James M. Durward	Contact Position CEO	Contact Telephone No. 403-689-3901
Contact Email Address jimd@ndatalyze.com	Web Site Address www.ndatalyze.com	